Derek Archila
Stock Analyst at Wells Fargo
(4.41)
# 361
Out of 5,111 analysts
210
Total ratings
56.2%
Success rate
16.87%
Average return
Main Sectors:
Stocks Rated by Derek Archila
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NRIX Nurix Therapeutics | Maintains: Overweight | $21 → $30 | $19.11 | +56.99% | 7 | Dec 16, 2025 | |
| KYTX Kyverna Therapeutics | Maintains: Overweight | $31 → $33 | $10.69 | +208.70% | 4 | Dec 16, 2025 | |
| IRON Disc Medicine | Maintains: Overweight | $91 → $109 | $91.00 | +19.78% | 1 | Dec 16, 2025 | |
| GLUE Monte Rosa Therapeutics | Upgrades: Overweight | $13 → $22 | $18.12 | +21.41% | 7 | Dec 16, 2025 | |
| ARGX argenx SE | Maintains: Overweight | $1,095 → $1,316 | $850.82 | +54.67% | 13 | Dec 11, 2025 | |
| KYMR Kymera Therapeutics | Maintains: Overweight | $69 → $116 | $86.07 | +34.77% | 10 | Dec 9, 2025 | |
| ORIC ORIC Pharmaceuticals | Maintains: Overweight | $19 → $25 | $9.39 | +166.24% | 2 | Dec 8, 2025 | |
| INCY Incyte | Maintains: Overweight | $97 → $116 | $97.44 | +19.05% | 11 | Dec 8, 2025 | |
| ANNX Annexon | Maintains: Overweight | $14 → $27 | $4.95 | +445.45% | 4 | Nov 19, 2025 | |
| SEPN Septerna | Upgrades: Overweight | $18 → $28 | $27.94 | +0.21% | 5 | Nov 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $76 → $84 | $75.57 | +11.16% | 1 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $395 → $479 | $395.69 | +21.05% | 1 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $11 → $14 | $8.37 | +67.26% | 5 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $16 → $15 | $12.30 | +21.95% | 8 | Nov 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $123 → $106 | $50.37 | +110.44% | 2 | Nov 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $51 → $81 | $44.61 | +81.59% | 4 | Nov 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $36 → $30 | $41.11 | -27.03% | 4 | Oct 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $7 → $5 | $6.25 | -19.94% | 12 | Oct 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $29 → $32 | $24.45 | +30.88% | 13 | Oct 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $5 → $10 | $2.43 | +311.52% | 6 | Sep 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $25 → $1 | $0.75 | +33.07% | 3 | Sep 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $44 → $38 | $26.88 | +41.37% | 4 | Aug 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $40 → $30 | $9.90 | +203.03% | 1 | Aug 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $3 → $2 | $2.47 | -19.03% | 11 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $289 → $295 | $206.25 | +43.03% | 14 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $6 → $5 | $1.43 | +249.65% | 5 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $27 → $26 | $32.69 | -20.46% | 2 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $17 | $11.26 | +51.00% | 1 | Jul 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $91 → $129 | $113.07 | +14.09% | 6 | Jul 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $16 → $15 | $2.94 | +410.20% | 2 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $12 → $14 | $26.01 | -46.17% | 5 | Dec 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $47 → $45 | $26.21 | +71.69% | 9 | Dec 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $37 → $20 | $3.78 | +429.10% | 7 | May 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $4.47 | +303.14% | 1 | Aug 4, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $298 → $193 | $31.31 | +516.51% | 1 | Jul 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $61 → $41 | $71.40 | -42.57% | 1 | Apr 15, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $480 → $160 | $13.99 | +1,043.67% | 3 | Mar 31, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $180 → $60 | $18.07 | +232.04% | 3 | Mar 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | $29 | $6.79 | +327.10% | 4 | Dec 11, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $34 → $50 | $1.39 | +3,497.12% | 2 | Jun 22, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $32 → $51 | $23.49 | +117.11% | 1 | Nov 15, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $88 | $12.92 | +581.11% | 1 | Sep 7, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | n/a | $26.65 | - | 1 | Sep 7, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $30.05 | - | 2 | Aug 3, 2017 |
Nurix Therapeutics
Dec 16, 2025
Maintains: Overweight
Price Target: $21 → $30
Current: $19.11
Upside: +56.99%
Kyverna Therapeutics
Dec 16, 2025
Maintains: Overweight
Price Target: $31 → $33
Current: $10.69
Upside: +208.70%
Disc Medicine
Dec 16, 2025
Maintains: Overweight
Price Target: $91 → $109
Current: $91.00
Upside: +19.78%
Monte Rosa Therapeutics
Dec 16, 2025
Upgrades: Overweight
Price Target: $13 → $22
Current: $18.12
Upside: +21.41%
argenx SE
Dec 11, 2025
Maintains: Overweight
Price Target: $1,095 → $1,316
Current: $850.82
Upside: +54.67%
Kymera Therapeutics
Dec 9, 2025
Maintains: Overweight
Price Target: $69 → $116
Current: $86.07
Upside: +34.77%
ORIC Pharmaceuticals
Dec 8, 2025
Maintains: Overweight
Price Target: $19 → $25
Current: $9.39
Upside: +166.24%
Incyte
Dec 8, 2025
Maintains: Overweight
Price Target: $97 → $116
Current: $97.44
Upside: +19.05%
Annexon
Nov 19, 2025
Maintains: Overweight
Price Target: $14 → $27
Current: $4.95
Upside: +445.45%
Septerna
Nov 14, 2025
Upgrades: Overweight
Price Target: $18 → $28
Current: $27.94
Upside: +0.21%
Nov 11, 2025
Maintains: Overweight
Price Target: $76 → $84
Current: $75.57
Upside: +11.16%
Nov 11, 2025
Maintains: Equal-Weight
Price Target: $395 → $479
Current: $395.69
Upside: +21.05%
Nov 7, 2025
Maintains: Overweight
Price Target: $11 → $14
Current: $8.37
Upside: +67.26%
Nov 6, 2025
Maintains: Overweight
Price Target: $16 → $15
Current: $12.30
Upside: +21.95%
Nov 5, 2025
Maintains: Overweight
Price Target: $123 → $106
Current: $50.37
Upside: +110.44%
Nov 5, 2025
Maintains: Overweight
Price Target: $51 → $81
Current: $44.61
Upside: +81.59%
Oct 21, 2025
Maintains: Equal-Weight
Price Target: $36 → $30
Current: $41.11
Upside: -27.03%
Oct 17, 2025
Maintains: Equal-Weight
Price Target: $7 → $5
Current: $6.25
Upside: -19.94%
Oct 15, 2025
Upgrades: Overweight
Price Target: $29 → $32
Current: $24.45
Upside: +30.88%
Sep 23, 2025
Maintains: Overweight
Price Target: $5 → $10
Current: $2.43
Upside: +311.52%
Sep 16, 2025
Downgrades: Equal-Weight
Price Target: $25 → $1
Current: $0.75
Upside: +33.07%
Aug 20, 2025
Maintains: Overweight
Price Target: $44 → $38
Current: $26.88
Upside: +41.37%
Aug 12, 2025
Maintains: Equal-Weight
Price Target: $40 → $30
Current: $9.90
Upside: +203.03%
Aug 8, 2025
Maintains: Equal-Weight
Price Target: $3 → $2
Current: $2.47
Upside: -19.03%
Aug 8, 2025
Maintains: Overweight
Price Target: $289 → $295
Current: $206.25
Upside: +43.03%
Aug 7, 2025
Maintains: Equal-Weight
Price Target: $6 → $5
Current: $1.43
Upside: +249.65%
Aug 7, 2025
Maintains: Equal-Weight
Price Target: $27 → $26
Current: $32.69
Upside: -20.46%
Jul 25, 2025
Initiates: Overweight
Price Target: $17
Current: $11.26
Upside: +51.00%
Jul 10, 2025
Maintains: Overweight
Price Target: $91 → $129
Current: $113.07
Upside: +14.09%
Mar 12, 2025
Maintains: Equal-Weight
Price Target: $16 → $15
Current: $2.94
Upside: +410.20%
Dec 19, 2024
Maintains: Equal-Weight
Price Target: $12 → $14
Current: $26.01
Upside: -46.17%
Dec 19, 2024
Maintains: Overweight
Price Target: $47 → $45
Current: $26.21
Upside: +71.69%
May 5, 2021
Downgrades: Hold
Price Target: $37 → $20
Current: $3.78
Upside: +429.10%
Aug 4, 2020
Initiates: Buy
Price Target: $18
Current: $4.47
Upside: +303.14%
Jul 10, 2020
Downgrades: Hold
Price Target: $298 → $193
Current: $31.31
Upside: +516.51%
Apr 15, 2020
Reiterates: Buy
Price Target: $61 → $41
Current: $71.40
Upside: -42.57%
Mar 31, 2020
Maintains: Hold
Price Target: $480 → $160
Current: $13.99
Upside: +1,043.67%
Mar 17, 2020
Downgrades: Hold
Price Target: $180 → $60
Current: $18.07
Upside: +232.04%
Dec 11, 2018
Downgrades: Perform
Price Target: $29
Current: $6.79
Upside: +327.10%
Jun 22, 2018
Maintains: Outperform
Price Target: $34 → $50
Current: $1.39
Upside: +3,497.12%
Nov 15, 2017
Maintains: Outperform
Price Target: $32 → $51
Current: $23.49
Upside: +117.11%
Sep 7, 2017
Initiates: Outperform
Price Target: $88
Current: $12.92
Upside: +581.11%
Sep 7, 2017
Initiates: Market Perform
Price Target: n/a
Current: $26.65
Upside: -
Aug 3, 2017
Downgrades: Perform
Price Target: n/a
Current: $30.05
Upside: -